We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+12.84%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.59B
AUM Growth
-$301M
(-6.2%)
Cap. Flow
-$430M
Cap. Flow
% of AUM
-9.37%
Top 10 Holdings %
Top 10 Hldgs %
42.8%
Holding
130
New
21
Increased
24
Reduced
35
Closed
20
Top Buys
| 1 |
AstraZeneca
AZN
|
+$129M |
| 2 |
Merck
MRK
|
+$76.6M |
| 3 |
Guardant Health
GH
|
+$43.7M |
| 4 |
Mineralys Therapeutics
MLYS
|
+$31.5M |
| 5 |
uniQure
QURE
|
+$28.3M |
Top Sells
| 1 |
TERN
Terns Pharmaceuticals
TERN
|
+$87M |
| 2 |
Eli Lilly
LLY
|
+$65.3M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$61M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$57.8M |
| 5 |
Cigna
CI
|
+$56.4M |
Sector Composition
| 1 | Healthcare | 99.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Syndax Pharmaceuticals
SNDX
$2.12B
| $22.5M | 0.49% |
+962,300
| New | +$20.9M |
|
52
BrightSpring Health Services
BTSG
$13.4B
| $21.2M | 0.46% |
497,800
+9,300
| +2% | +$375K |
|
53
Lexeo Therapeutics
LXEO
$365M
| $20.7M | 0.45% |
3,602,450
+1,477,450
| +70% | +$10.5M |
|
54
Sutro Biopharma
STRO
$440M
| $20M | 0.44% |
+801,144
| New | +$14.5M |
|
55
Nektar Therapeutics
NKTR
$2.27B
| $19.8M | 0.43% |
+275,000
| New | +$15.7M |
|
|
HELP
56
Cybin Inc
HELP
$402M
| $18.4M | 0.4% |
3,832,843
-7,657
| -0.2% | -$49.5K |
|
57
Krystal Biotech
KRYS
$10.1B
| $17.8M | 0.39% |
69,100
-50,700
| -42% | -$13.5M |
|
|
PVLA
58
Palvella Therapeutics
PVLA
$2.17B
| $16.8M | 0.37% |
+134,600
| New | +$14M |
|
59
Corbus Pharmaceuticals
CRBP
$168M
| $16.3M | 0.36% |
1,737,287
+140,000
| +9% | +$1.18M |
|
60
UroGen Pharma
URGN
$1.89B
| $15.7M | 0.34% |
875,487
| – | – |
|
|
DFTX
61
Definium Therapeutics
DFTX
$6.13B
| $15.2M | 0.33% |
804,000
-422,700
| -34% | -$7.17M |
|
62
Vera Therapeutics
VERA
$3.03B
| $14.9M | 0.32% |
369,596
+16,096
| +5% | +$693K |
|
63
Q32 Bio
QTTB
$298M
| $14.5M | 0.32% |
2,252,987
| – | – |
|
|
WHWK
64
Whitehawk Therapeutics
WHWK
$189M
| $14.4M | 0.31% |
4,166,000
| – | – |
|
65
Amgen
AMGN
$193B
| $14M | 0.31% |
+39,900
| New | +$14.2M |
|
66
Alignment Healthcare
ALHC
$4.21B
| $13.9M | 0.3% |
+791,000
| New | +$15.9M |
|
67
EyePoint Inc
EYPT
$1.16B
| $13.8M | 0.3% |
1,069,147
-1,399,167
| -57% | -$20.9M |
|
68
Janux Therapeutics
JANX
$970M
| $13.7M | 0.3% |
983,600
-970,826
| -50% | -$13.3M |
|
69
BioCryst Pharmaceuticals
BCRX
$2.41B
| $13.6M | 0.3% |
1,425,200
-316,600
| -18% | -$2.46M |
|
|
BCAX
70
Bicara Therapeutics
BCAX
$1.85B
| $13.3M | 0.29% |
667,300
+458,200
| +219% | +$7.89M |
|
|
BIOA
71
BioAge Labs
BIOA
$1.02B
| $12.4M | 0.27% |
711,811
-79,090
| -10% | -$1.52M |
|
72
Cogent Biosciences
COGT
$6.63B
| $12.4M | 0.27% |
322,100
-48,900
| -13% | -$1.81M |
|
|
ALMS
73
Alumis Inc
ALMS
$3.4B
| $12.1M | 0.26% |
548,163
-554,567
| -50% | -$13.9M |
|
74
Regeneron Pharmaceuticals
REGN
$69.5B
| $11.4M | 0.25% |
+14,700
| New | +$11.3M |
|
|
CARL
75
Carlsmed
CARL
$299M
| $11.3M | 0.25% |
1,252,600
| – | – |
|
Similar funds
CGI
LNWTC
SCM
AG
SCM
SV
ANTB
ECM